Updated clinical guidelines for adult bronchiectasis suggest long-term macrolide or brensocatib therapy to reduce frequent ...

ASPEN links green sputum to neutrophils and exacerbations; brensocatib (DPP1) lowers purulence, while meta-analysis supports ...

Individuals with non-cystic fibrosis bronchiectasis may experience partial cystic fibrosis transmembrane conductance regulator dysfunction (CFTR-RD) that can be identified and treated with highly ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Insmed introduces Brinsupri tablets 25 mg to treat non-cystic fibrosis bronchiectasis in Japan: Bridgewater, New Jersey Wednesday, October 21, 2026, 16:00 Hrs [IST] Insmed Incorpo ...

This article explains the role and future prospects of dipeptidyl peptidase 1 (DPP1) inhibitors as treatments for ...

Insmed (INSM) said Monday that it is launching a 25 mg tablet of Brinsupri in Japan to treat non-cystic fibrosis bronchiectasis, or NCFB, in adults and pediatric patients aged at ...

MPR: What is non-cystic fibrosis bronchiectasis? Dr Addrizzo-Harris: Non-cystic fibrosis bronchiectasis is an abnormality of the airways in the lung where the airways become dilated, often permanently ...

An abstract using U.S. Bronchiectasis and NTM Research Registry data comparing bronchiectasis in people with and without ...

Cindy has always been active. As a physical education teacher, and later an elementary school principal, she built her career ...

Imagine trying to live a normal life when you can’t stop coughing or you’re too breathless to walk. For many people living with bronchiectasis, that’s the reality they face every day. Recurring ...

Insmed Incorporated announced the commercial launch in Japan of BRINSUPRI Tablets 25 mg (brensocatib hydrate), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and ...